Condition: Recurrent Hairy Cell Leukemia · Recurrent Hairy Cell Leukemia Variant · Sponsor: National Cancer Institute (NCI)
This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Suspended |
| City of Hope at Irvine Lennar | Irvine, California, United States | Suspended |
| UM Sylvester Comprehensive Cancer Center at Aventura | Aventura, Florida, United States | Recruiting |
| UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables, Florida, United States | Recruiting |
| UM Sylvester Comprehensive Cancer Center at Coral Springs | Coral Springs, Florida, United States | Recruiting |
| UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach, Florida, United States | Recruiting |
| UM Sylvester Comprehensive Cancer Center at Doral | Doral, Florida, United States | Recruiting |
| UM Sylvester Comprehensive Cancer Center at Hollywood | Hollywood, Florida, United States | Recruiting |
| University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami, Florida, United States | Recruiting |
| UM Sylvester Comprehensive Cancer Center at Kendall | Miami, Florida, United States | Recruiting |
| University of Kansas Cancer Center | Kansas City, Kansas, United States | Recruiting |
| University of Kansas Cancer Center-Overland Park | Overland Park, Kansas, United States | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06311227